Literature DB >> 23386645

Serum concentrations of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2 and vitamin D3 supplementation.

Rachael M Biancuzzo1, Nigel Clarke, Richard E Reitz, Thomas G Travison, Michael F Holick.   

Abstract

OBJECTIVE: The purpose of this study was to determine 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and 1,25-dihydroxyvitamin D2 [1,25(OH)2D2] levels in healthy adults consuming 1000 IU vitamin D2 or vitamin D3 per day for 11 weeks. SUBJECTS AND
DESIGN: Blood from 34 healthy male and female adults, aged 18 to 79 years, from a placebo-controlled, double-blind study who received a placebo, 1000 IU vitamin D3, or 1000 IU vitamin D2 daily for 11 weeks at end of winter was analyzed. Serum levels of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, 1,25(OH)2D2, and 1,25(OH)2D3 were determined by liquid chromatography-tandem mass spectroscopy.
RESULTS: Of the adults, 82% were vitamin D insufficient (serum 25-hydroxyvitamin D [25(OH)D <30 ng/mL]) at the start of the study. Administration of vitamin D2 and vitamin D3 induced similar increases in total 25(OH)D as well as in 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, respectively. Compared with placebo and adjusting for baseline levels, 1000 IU daily of vitamin D2 was associated with a mean increase of 7.4 pg/mL (95% confidence interval, 4.4-10.3) in 1,25(OH)2D2, which was accompanied by a mean decrease of 9.9 pg/mL (-15.8 to -4.0) in 1,25(OH)2D3. No such differences accompanied administration of 1000 IU daily of vitamin D3.
CONCLUSION: Vitamin D2 and vitamin D3 were effective in raising and maintaining total serum concentrations of 25(OH)D. Ingestion of vitamin D2 also resulted in an increase in serum concentrations of 1,25(OH)2D2. This increase was accompanied by a comparable decrease in serum concentrations of 1,25(OH)2D3; therefore, the total 1,25-dihydroxyvitamin D [1,25(OH)2D] concentrations did not significantly change after 11 weeks compared with baseline levels. Ingestion of vitamin D3 did not alter serum concentrations of 1,25(OH)2D3 or total 1,25(OH)2D. Therefore, ingestion of 1000 IU vitamin D2 or vitamin D3 for 11 weeks was effective in raising total serum concentrations of 25(OH)D as well as sustaining serum concentrations of total 1,25(OH)2D.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23386645      PMCID: PMC3590486          DOI: 10.1210/jc.2012-2114

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

1.  Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.

Authors:  Philip T Liu; Steffen Stenger; Huiying Li; Linda Wenzel; Belinda H Tan; Stephan R Krutzik; Maria Teresa Ochoa; Jürgen Schauber; Kent Wu; Christoph Meinken; Diane L Kamen; Manfred Wagner; Robert Bals; Andreas Steinmeyer; Ulrich Zügel; Richard L Gallo; David Eisenberg; Martin Hewison; Bruce W Hollis; John S Adams; Barry R Bloom; Robert L Modlin
Journal:  Science       Date:  2006-02-23       Impact factor: 47.728

2.  Positive association between serum 25-hydroxyvitamin D level and bone density in osteoarthritis.

Authors:  Heike A Bischoff-Ferrari; Yuqing Zhang; Douglas P Kiel; David T Felson
Journal:  Arthritis Rheum       Date:  2005-12-15

3.  Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase.

Authors:  D Zehnder; R Bland; M C Williams; R W McNinch; A J Howie; P M Stewart; M Hewison
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

Review 4.  Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes.

Authors:  Heike A Bischoff-Ferrari; Edward Giovannucci; Walter C Willett; Thomas Dietrich; Bess Dawson-Hughes
Journal:  Am J Clin Nutr       Date:  2006-07       Impact factor: 7.045

5.  Vitamin D(3) is more potent than vitamin D(2) in humans.

Authors:  Robert P Heaney; Robert R Recker; James Grote; Ronald L Horst; Laura A G Armas
Journal:  J Clin Endocrinol Metab       Date:  2010-12-22       Impact factor: 5.958

6.  Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland).

Authors:  M H Ahonen; L Tenkanen; L Teppo; M Hakama; P Tuohimaa
Journal:  Cancer Causes Control       Date:  2000-10       Impact factor: 2.506

Review 7.  The role of vitamin D in cancer prevention.

Authors:  Cedric F Garland; Frank C Garland; Edward D Gorham; Martin Lipkin; Harold Newmark; Sharif B Mohr; Michael F Holick
Journal:  Am J Public Health       Date:  2005-12-27       Impact factor: 9.308

8.  Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study.

Authors:  E Hyppönen; E Läärä; A Reunanen; M R Järvelin; S M Virtanen
Journal:  Lancet       Date:  2001-11-03       Impact factor: 79.321

Review 9.  Vitamin D for health and in chronic kidney disease.

Authors:  Michael F Holick
Journal:  Semin Dial       Date:  2005 Jul-Aug       Impact factor: 3.455

10.  Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study.

Authors:  Susan Cheng; Joseph M Massaro; Caroline S Fox; Martin G Larson; Michelle J Keyes; Elizabeth L McCabe; Sander J Robins; Christopher J O'Donnell; Udo Hoffmann; Paul F Jacques; Sarah L Booth; Ramachandran S Vasan; Myles Wolf; Thomas J Wang
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

View more
  37 in total

1.  Down-regulation of IL-8 by high-dose vitamin D is specific to hyperinflammatory macrophages and involves mechanisms beyond up-regulation of DUSP1.

Authors:  N Dauletbaev; K Herscovitch; M Das; H Chen; J Bernier; E Matouk; J Bérubé; S Rousseau; L C Lands
Journal:  Br J Pharmacol       Date:  2015-10       Impact factor: 8.739

2.  Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial.

Authors:  James B Wetmore; Cassandra Kimber; Jonathan D Mahnken; Jason R Stubbs
Journal:  Br J Nutr       Date:  2017-01-09       Impact factor: 3.718

Review 3.  A therapeutic role for vitamin D on obesity-associated inflammation and weight-loss intervention.

Authors:  Aaron L Slusher; Matthew J McAllister; Chun-Jung Huang
Journal:  Inflamm Res       Date:  2015-07-04       Impact factor: 4.575

Review 4.  Vitamin D Metabolism and Guidelines for Vitamin D Supplementation.

Authors:  Indra Ramasamy
Journal:  Clin Biochem Rev       Date:  2020-12

5.  Time Course of Vitamin D Depletion and Repletion in Reproductive-age Female C57BL/6 Mice.

Authors:  Anthony M Belenchia; Sarah A Johnson; Alyssa C Kieschnick; Cheryl S Rosenfeld; Catherine A Peterson
Journal:  Comp Med       Date:  2017-12-01       Impact factor: 0.982

Review 6.  The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention.

Authors:  Michael F Holick
Journal:  Rev Endocr Metab Disord       Date:  2017-06       Impact factor: 6.514

7.  The effect of monthly 50,000 IU or 100,000 IU vitamin D supplements on vitamin D status in premenopausal Middle Eastern women living in Auckland.

Authors:  H Mazahery; W Stonehouse; P R von Hurst
Journal:  Eur J Clin Nutr       Date:  2014-12-10       Impact factor: 4.016

Review 8.  Vitamin D insufficiency and insulin resistance in obese adolescents.

Authors:  Catherine A Peterson; Aneesh K Tosh; Anthony M Belenchia
Journal:  Ther Adv Endocrinol Metab       Date:  2014-12       Impact factor: 3.565

9.  Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial.

Authors:  Deborah M Mitchell; Benjamin Z Leder; Enrico Cagliero; Natalia Mendoza; Maria P Henao; Douglas L Hayden; Joel S Finkelstein; Sherri-Ann M Burnett-Bowie
Journal:  Am J Clin Nutr       Date:  2015-07-08       Impact factor: 7.045

10.  Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol.

Authors:  Hala Alshayeb; Arif Showkat; Barry M Wall; Geeta G Gyamlani; Valentin David; L Darryl Quarles
Journal:  J Clin Endocrinol Metab       Date:  2014-06-24       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.